I wrote a post for the HIMSS blog in the week leading up to the…
I caught up recently with Eugene Borukhovich, aka @HealthEugene. Eugene is Global Head, Digital Health Incubation and Innovation at Bayer. He sees himself as standing at the crossroads of several streams of innovation and human endeavor – the intersection of digital and genomics, online engagement opportunities for patients and consumers, the life sciences perspective of “hacking our bodies from the inside,” and the health IT work being done to understand, aggregate and connect silos of data in a clinical setting – and sees digital health as an integrative superstructure, leveraging data that our bodies are generating 24/7 to make an impact on our behaviors.
Eugene continues to balance entrepreneurship with intrapreneurship, and conveys genuine excitement at the prospect of assisting the proverbial supertanker – a century-plus-old company with 100,000 employees across 100+ countries – to simultaneously “do better things, and do things better.” He observes that if everyone at Bayer were innovating and trying new things, the company would stop running.
Under the banner of a big company, Bayer has tried a number of different approaches to innovation – both top-down (identifying a problem to be solved internally and then recruiting externally to find a startup to help solve the problem) and bottom-up (encouraging innovation in the startup community through grantmaking, challenges, incubator programs, etc.). The company’s current approach is based on three pillars, all under the G4A (“Grants for Apps”) umbrella:
“Everyone loves change, but nobody wants to change.”
Working within three key areas of interest to Bayer — cardiology, oncology and women’s health — Eugene wants to “expand the swim lanes” as currently defined by the company, so as to make different areas of the company’s clinical focus as attractive as possible to innovators, while seeking to encourage development of the next generation of digital therapeutics – clinically-validated tools that go through a rigorous government approval process (which is still under development over at the FDA).
Thus far, this approach has taken Bayer into such diverse projects as building a better mousetrap for clinical trial recruitment, saliva-based detection of endometriosis and development of compound therapies in oncology.
When I asked him what he would hope to see five years from now, Eugene said he hopes that the more than seven billion people on our planet understand what drives our bodies, what makes them healthy. The only gloss I would add to that is a hope that we collectively act on that understanding.
I spoke with Eugene as part of my ongoing series of fireside chats with healthcare innovation leaders – Harlow on Healthcare, on HealthcareNOW Radio. You can catch me live weekdays at 8:30 am, 4:30 pm and 12:30 am ET. As each new show goes live, the last one joins the archive, available via SoundCloud or your favorite podcast app (iTunes, Stitcher, iHeartRadio). Your comments are welcome here. Join the conversation on Twitter at #HarlowOnHC.
David Harlow
The Harlow Group LLC
Health Care Law and Consulting
Healthcare NOW Radio Podcast Network · Harlow on Healthcare
In this episode I speak with Ryne Natzke, Chief Revenue Officer of TrustCommerce, a Sphere…
Natalie Davis, CEO of United States of Care, returned to Harlow on Healthcare to discuss…
If the EHR is the system of record, then Lumeon is the system of action.…
Blockchain in healthcare? Well, it can solve some problems. Have a listen to my conversation…
Joel Diamond, Chief Medical Officer at 2bPrecise, speaks with me about bringing genetic testing information…